SUPN Stock Supernus Pharmaceuticals (SUPN, $44.88) was a top quarterly gainer, rising +39.81%

GET DAILY SIGNALS

Get AI intraday signals

SUPN - Supernus Pharmaceuticals

Loading...

Price: $44.88

Daily change: +$1.56 (+3.6%)

Daily volume: 1M

3-month price change: +$12.78 (+39.81%)

Capitalization: $2.5B

Industry: Pharmaceuticals: Generic

SUPN in +1.37% Uptrend, rising for three consecutive days on September 11, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SUPN advanced for three days, in of 324 cases, the price rose further within the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for SUPN moved above the 200-day moving average on August 18, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

The Aroon Indicator entered an Uptrend today. In of 216 cases where SUPN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for SUPN moved out of overbought territory on September 12, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for SUPN turned negative on September 02, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SUPN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SUPN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.396) is normal, around the industry mean (17.281). P/E Ratio (39.530) is within average values for comparable stocks, (74.632). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). SUPN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (3.860) is also within normal values, averaging (46.794).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.